Cargando…
What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?
BACKGROUND: Progressive multifocal leukoencephalopathy is a serious condition linked to certain diseases and immunosuppressant therapies, including the α(4) integrin antagonist natalizumab. No cases have been reported to date with vedolizumab, a selective antagonist of the α(4)β(7) integrin expresse...
Autores principales: | Card, Timothy, Xu, Jing, Liang, Huifang, Bhayat, Fatima |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176885/ https://www.ncbi.nlm.nih.gov/pubmed/29668955 http://dx.doi.org/10.1093/ibd/izx097 |
Ejemplares similares
-
Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
por: Mahadevan, Uma, et al.
Publicado: (2018) -
Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient–Physician Visits
por: Rubin, David T., et al.
Publicado: (2017) -
Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
por: Lichtenstein, Gary R, et al.
Publicado: (2018) -
IBD LIVE Case Series–Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment?
por: Le, Peter N., et al.
Publicado: (2015) -
A Mobile Infliximab Dosing Calculator for Therapy Optimization in
Inflammatory Bowel Disease
por: Piester, Travis, et al.
Publicado: (2018)